Based on results of the PLATO ( Platelet Inhibition and Patient Outcomes ) trial comparing ticagrelor with clopidogrel therapy , the U.S. Food and Drug Administration approved ticagrelor in 2011 for reducing thrombotic cardiovascular events in patients with acute coronary syndrome ( ACS ) with the proviso that it be taken with low-dose aspirin .